. 2003 Dec 17;89(Suppl 3):S29–S34. doi: 10.1038/sj.bjc.6601498

Table 1. Response rates, time to progression and overall survival in patients with advanced ovarian cancer receiving second-line therapy with topotecan 1.5 mg m⁻² daily for 5 days (Gore et al, 2000).

Treatment group	No. of patients evaluable for clinical response	Overall response rate (%)	Complete response rate (%)	Median time to progression (weeks)	Median overall survival (months)
Platinum+paclitaxel-refractory	48	6.3	0	13.4	45.2
Platinum+paclitaxel-resistanta	33	12.1	0	15.1	45.3
Platinum+paclitaxel-sensitiveb	35	37.1	11.4	31.6	98.6

Relapse within 6 months of first-line therapy.

Relapse more than 6 months after first-line therapy.

Table 1. Response rates, time to progression and overall survival in patients with advanced ovarian cancer receiving second-line therapy with topotecan 1.5 mg m−2 daily for 5 days (Gore et al, 2000).